Comirnaty mRNA COVID-19 vaccine explained for US users

Comirnaty, the Pfizer-BioNTech mRNA COVID-19 vaccine, remains a key tool to help prevent severe COVID-19 in the US. Here is how it works, who uses it, and why it still matters.

Comirnaty, the Pfizer-BioNTech COVID-19 vaccine, was the first mRNA COVID-19 vaccine to receive full FDA approval for adults on 08/23/2021, according to the US Food and Drug Administration FDA, 08/23/2021.

Updated: 05/17/2026 | Reading time: approx. 10 minutes

By the AD HOC NEWS editorial team - specialized in product-led market coverage.

At a Glance

• Product: Comirnaty COVID-19 Vaccine
• Category: mRNA-based COVID-19 vaccine
• Brand/Manufacturer: Pfizer-BioNTech
• Main Use Cases: Prevention of symptomatic COVID-19
• Availability: Prescription use through US health providers
• Key Markets: United States and multiple global regions

What Comirnaty COVID-19 Vaccine Is and How It Works

Comirnaty is an mRNA vaccine that delivers genetic instructions for the SARS-CoV-2 spike protein, prompting the immune system to recognize and respond to the virus, as described by the US Centers for Disease Control and Prevention CDC, 01/11/2023.

Unlike traditional vaccines that may use inactivated viruses, mRNA vaccines such as Comirnaty use a lipid nanoparticle to protect the mRNA until it enters human cells, where it is translated into spike protein fragments and then broken down, according to the CDC CDC, 01/11/2023.

The body recognizes these spike protein fragments as foreign and builds an immune response, including antibodies and T-cell responses, which can help reduce the risk of symptomatic and severe COVID-19 if the vaccinated person is later exposed to SARS-CoV-2, as outlined by the World Health Organization WHO, 12/14/2021.

Why Comirnaty COVID-19 Vaccine Matters for Consumers and Industry

Comirnaty has been an important tool in reducing the burden of severe COVID-19, which has had major public health and economic impacts in the United States, according to the CDC CDC, 03/16/2023.

Widespread use of COVID-19 vaccines such as Comirnaty has been associated with fewer hospitalizations compared with the early pandemic period before vaccination campaigns, as described in an analysis published by the New England Journal of Medicine NEJM, 12/23/2021.

For employers and industries, the availability of mRNA vaccines has supported safer in-person work, more stable operations, and reduced disruptions linked to outbreaks, according to a report discussing workplace vaccination programs in the Journal of Occupational and Environmental Medicine JOEM, 06/01/2021.

Comirnaty COVID-19 Vaccine in the US and Global Market

In the United States, Comirnaty has been distributed through federal and state vaccination programs, retail pharmacies, and health systems, as described in US government materials on the federal COVID-19 vaccination program HHS, 09/09/2022.

The vaccine has been part of the portfolio of COVID-19 vaccines recommended for specific age groups and risk groups in CDC immunization guidance, which has been updated over time to reflect evolving evidence and variants CDC, 02/22/2024.

Globally, the Pfizer-BioNTech mRNA vaccine has been used in many countries under different brand names or regulatory pathways, supported by emergency use listings and national approvals, according to the World Health Organization COVID-19 vaccine tracker WHO, 03/15/2024.

• mRNA-based design tailored to SARS-CoV-2 spike protein
• Lipid nanoparticle carrier that protects mRNA
• Intramuscular injection, typically in the upper arm
• Used in the US for prevention of symptomatic COVID-19
• Subject to FDA regulation and CDC immunization guidance

Frequently Asked Questions About Comirnaty COVID-19 Vaccine

How is Comirnaty given in the United States?
Comirnaty is administered as an intramuscular injection in the upper arm by a trained health professional in clinics, pharmacies, or vaccination centers, as noted by the CDC in its provider guidance CDC, 01/05/2023.

Who regulates Comirnaty for the US market?
The US Food and Drug Administration regulates Comirnaty for safety, effectiveness, and quality, and the CDC provides immunization recommendations, as explained in joint FDA and CDC COVID-19 materials FDA, 10/19/2023.

Where can US residents get reliable information on Comirnaty?
US residents can review detailed information on Comirnaty in FDA fact sheets for recipients and caregivers and in CDC vaccine pages that explain indications, dosing, and potential side effects FDA, 09/11/2023.

Comirnaty is marketed in collaboration between BioNTech SE, a biotechnology company based in Germany, and Pfizer Inc., a large US-based pharmaceutical company, as explained on the BioNTech corporate website BioNTech, 04/02/2024.

BioNTech SE shares are listed on the Nasdaq exchange in the United States under the ticker BNTX, and the company has the ISIN US09075V1026, according to Nasdaq listing data Nasdaq, 03/20/2024.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.